Gateway Biotechnology, Inc.

Privately owned biotechnology company focused specifically on drug products for tinnitus and hearing disorders. Developer of GW-TT2 (intranasal nimodipine), GW-TT3 (an undisclosed novel small molecule), and GW-TT5 (an AAV gene therapy). GW-TT2 received a $1.3M Defense Health Program research grant.